Randomized trial assesses Tocilizumab's effectiveness in Systemic Sclerosis-related domains, highlighting safety and efficacy.
Key Points
The study aims to evaluate the real-life safety and effectiveness of Tocilizumab in treating patients with Systemic Sclerosis and its related complications.
Retrospective analysis of 197 patients with Systemic Sclerosis treated with Tocilizumab across 15 referral centres.
Data were collected at baseline, 12, and 24 months, focusing on modified Rodnan skin score, pulmonary function tests, digital ulcers, and cardiac biomarkers.
ILD progression was assessed using percentage decline in forced vital capacity over 12±3 months.
%pFVC significantly declined from 81% at baseline to 77% after 12 months (p=0.003).
Proportion of ILD progressors decreased from 43% to 24% post-Tocilizumab initiation (p=0.015).
Improvements noted in mRSS among diffuse cutaneous patients, with infections being the most frequent adverse event (22.8%).